{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:41:19Z","timestamp":1781134879552,"version":"3.54.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.cllc.2019.08.003","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T19:29:26Z","timestamp":1567193366000},"page":"66-74.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Development of a Novel Prognostic Risk Classification System for Malignant Pleural Mesothelioma"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3237-2119","authenticated-orcid":false,"given":"Hiroshi","family":"Doi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Kuribayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Kitajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Yamakado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2019.08.003_bib1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jtho.2015.11.005","article-title":"The 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification","volume":"11","author":"Galateau-Salle","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.08.003_bib2","first-page":"491","article-title":"Malignant pleural mesothelioma: an epidemiological perspective","volume":"1","author":"Robinson","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.cllc.2019.08.003_bib3","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Malignant Pleural Mesothelioma Version 1.2019. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpm.pdf. Accessed February 18, 2019."},{"issue":"Suppl 5","key":"10.1016\/j.cllc.2019.08.003_bib4","doi-asserted-by":"crossref","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2019.08.003_bib5","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1097\/JTO.0b013e3182208e3f","volume":"6","author":"Rice","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.08.003_bib6","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1200\/JCO.2017.73.8401","article-title":"Long-term survival outcomes of cancer-directed surgery for malignant pleural mesothelioma: propensity score matching analysis","volume":"35","author":"Nelson","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2019.08.003_bib7","doi-asserted-by":"crossref","first-page":"562","DOI":"10.21037\/tlcr.2018.10.02","article-title":"Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations","volume":"7","author":"De Bondt","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2019.08.003_bib8","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/ejcts\/ezy385","article-title":"Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy","volume":"55","author":"Frick","year":"2019","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.cllc.2019.08.003_bib9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jtho.2018.02.021","article-title":"Progress in the management of malignant pleural mesothelioma in 2017","volume":"13","author":"McCambridge","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.08.003_bib10","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1007\/s13277-014-1938-5","article-title":"Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma","volume":"35","author":"Yao","year":"2014","journal-title":"Tumour Biol"},{"key":"10.1016\/j.cllc.2019.08.003_bib11","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10147-015-0925-1","volume":"21","author":"Hasegawa","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.cllc.2019.08.003_bib12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2019.08.003_bib13","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1378\/chest.108.4.1122","article-title":"A\u00a0proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group","volume":"108","author":"Rusch","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.cllc.2019.08.003_bib14","series-title":"TNM Classification of Malignant Tumours","author":"Brierley","year":"2016"},{"key":"10.1016\/j.cllc.2019.08.003_bib15","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/JTO.0b013e31815608d9","article-title":"Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center","volume":"2","author":"Flores","year":"2007","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.08.003_bib16","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.ejcts.2009.12.039","article-title":"Surgical assessment of malignant pleural mesothelioma: have we reached a critical stage?","volume":"37","author":"Nakas","year":"2010","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.cllc.2019.08.003_bib17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1759-7714.2012.00127.x","article-title":"Clinical and biologic prognostic factors in malignant pleural mesothelioma","volume":"3","author":"Ambrogi","year":"2012","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.cllc.2019.08.003_bib18","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1245\/s10434-010-1107-z","article-title":"Volume-based parameter of 18 F-FDG PET\/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications","volume":"17","author":"Lee","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.cllc.2019.08.003_bib19","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1158\/1078-0432.CCR-09-2313","article-title":"A\u00a0novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters","volume":"16","author":"Nowak","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2019.08.003_bib20","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/MNM.0b013e3283653862","article-title":"Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy\/decortication","volume":"34","author":"Bille","year":"2013","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.cllc.2019.08.003_bib21","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00259-013-2561-1","article-title":"The association of 18 F-FDG PET\/CT parameters with survival in malignant pleural mesothelioma","volume":"41","author":"Klabatsa","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cllc.2019.08.003_bib22","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00259-014-2960-y","article-title":"Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma","volume":"42","author":"Lopci","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cllc.2019.08.003_bib23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/MNM.0000000000000402","article-title":"The potential value of volume-based quantitative PET parameters and increased bone marrow uptake for the prediction of survival in patients with malignant pleural mesothelioma","volume":"37","author":"Ozmen","year":"2016","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.cllc.2019.08.003_bib24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejrad.2016.11.019","article-title":"Prognostic value of pretreatment volume-based quantitative 18F-FDG PET\/CT parameters in patients with malignant pleural mesothelioma","volume":"86","author":"Kitajima","year":"2017","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.cllc.2019.08.003_bib25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s13665-013-0045-1","article-title":"Prognostic factors for malignant pleural mesothelioma","volume":"2","author":"Brims","year":"2013","journal-title":"Curr Respir Care Rep"},{"key":"10.1016\/j.cllc.2019.08.003_bib26","first-page":"1898","article-title":"Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy","volume":"7","author":"Tagawa","year":"2015","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.cllc.2019.08.003_bib27","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1158\/1078-0432.CCR-10-2245","article-title":"High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy","volume":"16","author":"Kao","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2019.08.003_bib28","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cllc.2012.03.011","article-title":"Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board","volume":"14","author":"Kao","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2019.08.003_bib29","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1097\/JTO.0b013e31822a3740","article-title":"Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy","volume":"6","author":"Kao","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.08.003_bib30","doi-asserted-by":"crossref","first-page":"57460","DOI":"10.18632\/oncotarget.15404","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2019.08.003_bib31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience","volume":"16","author":"Curran","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2019.08.003_bib32","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2005.07.050","article-title":"Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials","volume":"23","author":"Fennell","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2019.08.003_bib33","doi-asserted-by":"crossref","first-page":"232","DOI":"10.21037\/atm.2017.03.82","article-title":"Extrapleural pneumonectomy (EPP) vs. pleurectomy decortication (P\/D)","volume":"5","author":"Batirel","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.cllc.2019.08.003_bib34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/JTO.0000000000000064","article-title":"Does surgery improve survival of patients with malignant pleural mesothelioma? A multicenter retrospective analysis of 1365 consecutive patients","volume":"9","author":"Bovolato","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.08.003_bib35","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4149\/neo_2017_114","article-title":"Elevated aspartate aminotransferase and monocyte counts predict unfavorable prognosis in patients with malignant pleural mesothelioma","volume":"64","author":"Zhang","year":"2017","journal-title":"Neoplasma"},{"key":"10.1016\/j.cllc.2019.08.003_bib36","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1038\/onc.2011.576","article-title":"Metabolic reprogramming of the tumor","volume":"31","author":"Ferreira","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.cllc.2019.08.003_bib37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1471-2407-11-167","article-title":"Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1alpha, CAIX, LDH-5, GLUT-1, MCT1 and MCT4","volume":"11","author":"Rademakers","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cllc.2019.08.003_bib38","doi-asserted-by":"crossref","first-page":"6921","DOI":"10.1158\/0008-5472.CAN-11-1457","article-title":"Lactate: a metabolic key player in cancer","volume":"71","author":"Hirschhaeuser","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2019.08.003_bib39","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.semradonc.2004.04.004","article-title":"Lactate: mirror and motor of tumor malignancy","volume":"14","author":"Walenta","year":"2004","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.cllc.2019.08.003_bib40","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","article-title":"Cancer-related inflammation and treatment effectiveness","volume":"15","author":"Diakos","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2019.08.003_bib41","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.4049\/jimmunol.141.12.4395","article-title":"Suppression of lymphokine-activated killer induction by neutrophils","volume":"141","author":"Shau","year":"1988","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.cllc.2019.08.003_bib42","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1023\/B:AGEN.0000029415.62384.ba","article-title":"Platelets\u00a0and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor","volume":"6","author":"Kusumanto","year":"2003","journal-title":"Angiogenesis"},{"key":"10.1016\/j.cllc.2019.08.003_bib43","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.1158\/1078-0432.CCR-18-1231","article-title":"Gemcitabine synergizes with immune checkpoint inhibitors and overcomes resistance in a preclinical model and mesothelioma patients","volume":"24","author":"Tall\u00f3n de Lara","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2019.08.003_bib44","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.08.003_bib45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.21037\/tlcr.2017.05.02","article-title":"Immunotherapy for malignant pleural mesothelioma: current status and future directions","volume":"6","author":"Dozier","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2019.08.003_bib46","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","article-title":"Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical\u2013pathological features and intratumor heterogeneity over time","volume":"29","author":"Pasello","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2019.08.003_bib47","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab","volume":"111","author":"Diem","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2019.08.003_bib48","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.113.3.723","article-title":"Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B","volume":"113","author":"Herndon","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.cllc.2019.08.003_bib49","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jtho.2015.12.108","article-title":"A\u00a0novel clinical prediction model for prognosis in malignant pleural mesothelioma using decision tree analysis","volume":"11","author":"Brims","year":"2016","journal-title":"J\u00a0Thorac Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730419302529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730419302529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:10:13Z","timestamp":1761505813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730419302529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1525730419302529"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2019.08.003","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a Novel Prognostic Risk Classification System for Malignant Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2019.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}